The Cansino Hong Kong Stock Exchange announced that the recombinant pneumococcal protein vaccine (PBPV) developed by the company obtained positive initial results in phase I (including phase Ia and phase Ib) clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.